Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gossamer Bio, Inc. (GOSS)
USD0.17
+0.01 (+3.28%)
US NASDAQ Healthcare Biotechnology
Address
3115 Merryfield Row 92121
San Diego, CA, US
San Diego, CA, US
CEO
Faheem Hasnain
Website
gossamerbio.com
IPO
2019-02-08
CIK 1728117 ISIN US38341P1021
Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.17
+0.01 (+3.28%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
12M
Beta
2.01
Float Shares
205.35M
Free Float %
87.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.03% | +4.68% | -23.77% | -84.19% | -88.63% | -89.03% | -68.81% | -74.24% | -96.11% | -98.10% | -98.10% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (17 ratings, all time)
Buy
Price Targets & DCF
Current price
0.17
Low
0.30
+73.2%
Consensus
0.77
+342.7%
Median
1.00
+477.4%
High
1.00
+477.4%
DCF (Unlevered)
0.95
+449.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 3 |
0.77
+342.7%
|
| Last Year | 5 |
4.06
+2,244.1%
|
| All Time | 11 |
5.21
+2,908.1%
|
Quality scores
Altman Z-Score
-19.31
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-57.7% Q1'26: +71.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-200.0% Q1'26: -25.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-385.5% Q1'26: -228.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-336.8% Q1'26: -264.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +305.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.0% ★ Q1'26: +3.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.24× Q1'26: -1.13× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 6 EPS Ana. |
Dec 2027 6 Rev. Ana. 6 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 95.84M (-100.0%)
|
114.70M
est: 112.15M (+2.3%)
|
48.47M
est: 42.20M (+14.9%)
|
17.75M
8.52M – 27.70M
-57.9% YoY
|
49.66M
19.41M – 110.02M
+179.7% YoY
|
119.32M
119.32M – 119.32M
+140.3% YoY
|
242.95M
99.47M – 515.36M
+103.6% YoY
|
354.45M
145.12M – 751.87M
+45.9% YoY
|
| EBITDA |
-161.92M
est: 31.66M (-611.5%)
|
-39.97M
est: 37.04M (-207.9%)
|
-162.25M
est: 13.94M (-1,264.0%)
|
5.86M
2.81M – 9.15M
-57.9% YoY
|
16.40M
6.41M – 36.34M
+179.7% YoY
|
39.41M
39.41M – 39.41M
+140.3% YoY
|
80.25M
32.86M – 170.23M
+103.6% YoY
|
117.08M
47.93M – 248.35M
+45.9% YoY
|
| EBIT |
-166.31M
est: 30.96M (-637.1%)
|
-44.12M
est: 36.23M (-221.8%)
|
-163.25M
est: 13.63M (-1,297.4%)
|
5.73M
2.75M – 8.95M
-57.9% YoY
|
16.04M
6.27M – 35.54M
+179.7% YoY
|
38.55M
38.55M – 38.55M
+140.3% YoY
|
78.49M
32.14M – 166.50M
+103.6% YoY
|
114.51M
46.88M – 242.91M
+45.9% YoY
|
| Net Income |
-179.82M
est: -80.85M (-122.4%)
|
-56.53M
est: -57.64M (+1.9%)
|
-170.37M
est: -170.37M (+0.0%)
|
-131.61M
-167.68M – -42.45M
+22.8% YoY
|
-65.00M
-70.81M – -9.88M
+50.6% YoY
|
3.05M
-558.77M – 466.82M
+104.7% YoY
|
36.56M
8.49M – 89.86M
+1,100.0% YoY
|
53.02M
12.31M – 130.29M
+45.0% YoY
|
| SGA |
38.46M
est: 78.43M (-51.0%)
|
36.13M
est: 91.77M (-60.6%)
|
37.63M
est: 34.53M (+9.0%)
|
14.53M
6.97M – 22.66M
-57.9% YoY
|
40.63M
15.88M – 90.03M
+179.7% YoY
|
97.63M
97.63M – 97.63M
+140.3% YoY
|
198.80M
81.39M – 421.70M
+103.6% YoY
|
290.03M
118.75M – 615.23M
+45.9% YoY
|
| EPS |
-0.80
est: -0.37 (-115.7%)
|
-0.25
est: -0.28 (+11.5%)
|
-0.75
est: -0.74 (-1.2%)
|
-0.46
-0.73 – -0.19
+38.6% YoY
|
-0.17
-0.31 – -0.04
+63.6% YoY
|
-0.02
-2.45 – 2.04
+88.8% YoY
|
0.16
0.04 – 0.39
+961.6% YoY
|
0.23
0.05 – 0.57
+45.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-198.50M
OE per share TTM
-0.87
Owner's Yield
-249.35%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
40.8%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
124
Total invested
21.00M
Insider transactions (90d)
0
Beneficial owners (>5%)
40
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 27.84M | 29.47% | — | 27.73M | — | 27.84M | HC | BOSTON, MASSACHUSETTS | 2023-01-10 | ↗ |
| 2 | SSGA FUNDS MANAGEMENT, INC. | 26.62M | 28.17% | — | 26.60M | — | 26.62M | IA | BOSTON, MASSACHUSETTS | 2023-01-10 | ↗ |
| 3 | Ali Behbahani | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 4 | Anthony A. Florence, Jr. | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 5 | Carmen Chang | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 6 | Edward T. Mathers | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 7 | Growth Equity Opportunities 18 VGE, LLC | 18.79M | 8.20% | — | 18.79M | — | 18.79M | OO | Delaware Limited Liability Company | 2023-07-28 | ↗ |
| 8 | Mohamad H. Makhzoumi | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 9 | NEA 18 VGE GP, LLC | 18.79M | 8.20% | — | 18.79M | — | 18.79M | OO | Limited Liability Company | 2023-07-28 | ↗ |
| 10 | NEA 18 Venture Growth Equity, L.P. | 18.79M | 8.20% | — | 18.79M | — | 18.79M | PN | Delaware Limited Partnership | 2023-07-28 | ↗ |
| 11 | NEA Partners 18 VGE, L.P. | 18.79M | 8.20% | — | 18.79M | — | 18.79M | PN | Delaware Limited Partnership | 2023-07-28 | ↗ |
| 12 | Paul Walker | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 13 | Rick Yang | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 14 | Scott D. Sandell | 18.79M | 8.20% | — | 18.79M | — | 18.79M | IN | States | 2023-07-28 | ↗ |
| 15 | Artal Group S.A. | 13.11M | 5.80% | 13.11M | — | 13.11M | — | OO | Bermuda | 2024-01-11 | ↗ |
| 16 | Artal International Management S.A. | 13.11M | 5.80% | 13.11M | — | 13.11M | — | OO | Bermuda | 2024-01-11 | ↗ |
| 17 | Artal International S.C.A. | 13.11M | 5.80% | 13.11M | — | 13.11M | — | OO | Bermuda | 2024-01-11 | ↗ |
| 18 | Invus Public Equities Advisors, LLC | 13.11M | 5.80% | 13.11M | — | 13.11M | — | OO | Bermuda | 2024-01-11 | ↗ |
| 19 | Invus Public Equities, L.P. | 13.11M | 5.80% | 13.11M | — | 13.11M | — | PN | Bermuda | 2024-01-11 | ↗ |
| 20 | Mr. Amaury Wittouck | 13.11M | 5.80% | 13.11M | — | 13.11M | — | IN | Bermuda | 2024-01-11 | ↗ |
| 21 | Stichting Administratiekantoor Westend | 13.11M | 5.80% | 13.11M | — | 13.11M | — | OO | Bermuda | 2024-01-11 | ↗ |
| 22 | Westend S.A. | 13.11M | 5.80% | 13.11M | — | 13.11M | — | OO | Bermuda | 2024-01-11 | ↗ |
| 23 | Abigail P. Johnson | 12.26M | 5.44% | — | — | 12.26M | — | IN | United States of America | 2024-02-09 | ↗ |
| 24 | FMR LLC | 12.26M | 5.44% | 12.19M | — | 12.26M | — | HC | Delaware | 2024-02-09 | ↗ |
| 25 | ARCH Venture Fund IX Overage, L.P. | 8.06M | 12.20% | — | 8.06M | — | 8.06M | PN | — | 2020-02-13 | ↗ |
| 26 | ARCH Venture Fund IX, L.P. | 8.06M | 12.20% | — | 8.06M | — | 8.06M | PN | — | 2020-02-13 | ↗ |
| 27 | ARCH Venture Partners IX, LLC | 8.06M | 12.20% | — | 8.06M | — | 8.06M | OO | — | 2020-02-13 | ↗ |
| 28 | Clinton Bybee | 8.06M | 12.20% | — | 8.06M | — | 8.06M | IN | — | 2020-02-13 | ↗ |
| 29 | Keith Crandell | 8.06M | 12.20% | — | 8.06M | — | 8.06M | IN | — | 2020-02-13 | ↗ |
| 30 | Robert Nelsen | 8.06M | 12.20% | — | 8.06M | — | 8.06M | IN | — | 2020-02-13 | ↗ |
| 31 | of 11 Pages | 6.12M | 9.30% | — | 6.12M | — | 6.12M | OO | Cayman Islands | 2020-02-14 | ↗ |
| 32 | Hillhouse Capital Advisors, Ltd. | 5.91M | 9.00% | — | 5.91M | — | — | IA | Cayman Islands | 2020-02-14 | ↗ |
| 33 | Hillhouse Capital Management, Ltd. | 5.91M | 9.00% | — | 5.91M | — | — | IA | Cayman Islands | 2020-02-14 | ↗ |
| 34 | The Vanguard Group - 23-1945930 | 5.59M | 7.31% | — | 46.3K | 5.50M | 85.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 35 | (1) BlackRock, Inc. | 5.43M | 7.10% | 5.22M | — | 5.43M | — | HC | Delaware | 2022-02-03 | ↗ |
| 36 | Israel A. Englander | 4.80M | 5.10% | — | 4.80M | — | 4.80M | IN | — | 2023-01-04 | ↗ |
| 37 | Millennium Group Management LLC | 4.80M | 5.10% | — | 4.80M | — | 4.80M | OO | — | 2023-01-04 | ↗ |
| 38 | Millennium Management LLC | 4.80M | 5.10% | — | 4.80M | — | 4.80M | OO | — | 2023-01-04 | ↗ |
| 39 | Sheila Gujrathi | 3.61M | 4.80% | 3.61M | — | 3.61M | — | IN | United States | 2021-02-12 | ↗ |
| 40 | Faheem Hasnain | 3.50M | 4.60% | 3.50M | — | 3.50M | — | IN | United States | 2021-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
124
-92 vs prev Q
New positions
35
Closed positions
111
Increased
77
Reduced
32
Put/Call ratio
0.05
Calls held
678.9K
Puts held
34.1K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NEA MANAGEMENT COMPANY, LLC | 18.09M +— (+0.0%) | 56.09M +8.5M (+17.9%) | 7.94% -0.025 pp | 2.86% +0.249 pp | USD2.98 +4.0% | 14 qtrs — |
| 2 | BLACKROCK, INC. | 17.06M +3.2M (+23.2%) | 52.88M +16.5M (+45.2%) | 7.48% +1.390 pp | 0.00% +0.000 pp | USD1.68 +84.5% | 6 qtrs — |
| 3 | OCTAGON CAPITAL ADVISORS LP | 13.92M -3.1M (-18.4%) | 43.14M -1.7M (-3.8%) | 6.10% -1.398 pp | 5.24% -1.560 pp | USD1.82 +70.3% | 21 qtrs — |
| 4 | VANGUARD GROUP INC | 12.87M +863.4K (+7.2%) | 39.91M +8.3M (+26.3%) | 5.65% +0.362 pp | 0.00% +0.000 pp | USD4.22 -26.5% | 28 qtrs — |
| 5 | STATE STREET CORP | 9.31M +5.4M (+139.7%) | 28.86M +18.6M (+182.6%) | 4.08% +2.375 pp | 0.00% +0.001 pp | USD2.59 +19.7% | 28 qtrs — |
| 6 | ARCH VENTURE MANAGEMENT, LLC | 8.06M +— (+0.0%) | 24.97M +3.8M (+17.9%) | 3.53% -0.011 pp | 3.83% -0.471 pp | USD0.83 +273.5% | 10 qtrs — |
| 7 | SAMSARA BIOCAPITAL, LLC | 7.22M +1.1M (+17.8%) | 22.39M +6.3M (+38.9%) | 3.17% +0.471 pp | 2.31% +0.205 pp | USD1.18 +162.7% | 10 qtrs — |
| 8 | SIREN, L.L.C. | 5.21M +— (+0.0%) | 16.15M +2.4M (+17.9%) | 2.28% -0.007 pp | 0.48% -0.054 pp | USD0.99 +213.1% | 6 qtrs — |
| 9 | 683 CAPITAL MANAGEMENT, LLC | 5.19M +131.6K (+2.6%) | 16.09M +2.8M (+20.9%) | 2.28% +0.051 pp | 0.70% +0.005 pp | USD0.97 +219.6% | 10 qtrs — |
| 10 | HHLR ADVISORS, LTD. | 4.97M +— (+0.0%) | 15.42M +2.3M (+17.9%) | 2.18% -0.007 pp | 0.50% +0.177 pp | USD16.51 -81.2% | 28 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 4.87M +183.2K (+3.9%) | 15.11M +2.8M (+22.5%) | 2.14% +0.074 pp | 0.00% +0.000 pp | USD3.10 +0.0% | 28 qtrs — |
| 12 | PALO ALTO INVESTORS LP | 4.47M -992.8K (-18.2%) | 13.86M -509.3K (-3.5%) | 1.96% -0.443 pp | 1.93% -0.730 pp | USD1.13 +174.3% | 23 qtrs — |
| 13 | ACADIAN ASSET MANAGEMENT LLC | 4.42M -596.1K (-11.9%) | 13.69M +506.0K (+3.8%) | 1.94% -0.268 pp | 0.02% -0.001 pp | USD1.20 +158.3% | 13 qtrs — |
| 14 | FMR LLC | 4.24M +152.2K (+3.7%) | 13.14M +2.4M (+22.3%) | 1.86% +0.061 pp | 0.00% +0.000 pp | USD0.99 +213.1% | 28 qtrs — |
| 15 | CI PRIVATE WEALTH, LLC | 3.85M +3.8M (+19,123.7%) | 11.92M +11.9M (+22,559.0%) | 1.69% +1.678 pp | 0.02% +0.016 pp | USD3.09 +0.3% | 13 qtrs — |
| 16 | MILLENNIUM MANAGEMENT LLC | 3.58M -35.0K (-1.0%) | 11.11M +1.6M (+16.7%) | 1.57% -0.020 pp | 0.00% +0.001 pp | USD2.53 +22.5% | 25 qtrs — |
| 17 | TWO SIGMA INVESTMENTS, LP | 3.40M +1.1M (+48.5%) | 10.53M +4.5M (+75.1%) | 1.49% +0.484 pp | 0.01% +0.006 pp | USD2.24 +38.4% | 24 qtrs — |
| 18 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.27M +— (+0.0%) | 10.13M +1.5M (+17.9%) | 1.43% -0.005 pp | 0.52% +0.017 pp | USD2.21 +40.3% | 14 qtrs — |
| 19 | PERCEPTIVE ADVISORS LLC | 3.14M -673.1K (-17.7%) | 9.73M -294.7K (-2.9%) | 1.38% -0.301 pp | 0.17% -0.116 pp | USD2.63 +17.9% | 2 qtrs — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.97M -330.9K (-10.0%) | 9.21M +526.0K (+6.1%) | 1.30% -0.150 pp | 0.00% +0.000 pp | USD2.07 +49.8% | 23 qtrs — |
| 21 | OPALEYE MANAGEMENT INC. | 2.72M -5.0K (-0.2%) | 8.43M +1.3M (+17.7%) | 1.19% -0.006 pp | 1.11% +0.099 pp | USD1.01 +206.9% | 11 qtrs — |
| 22 | TWO SIGMA ADVISERS, LP | 2.60M +726.8K (+38.9%) | 8.05M +3.1M (+63.7%) | 1.14% +0.316 pp | 0.02% +0.006 pp | USD3.28 -5.5% | 23 qtrs — |
| 23 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2.18M +769.9K (+54.7%) | 6.75M +3.0M (+82.3%) | 0.96% +0.336 pp | 0.03% +0.011 pp | USD2.06 +50.5% | 9 qtrs — |
| 24 | SILVERARC CAPITAL MANAGEMENT, LLC | 2.14M -2.6M (-55.3%) | 6.62M -5.9M (-47.3%) | 0.94% -1.166 pp | 0.92% -0.775 pp | USD0.85 +264.7% | 10 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 1.91M -975.2K (-33.8%) | 5.91M -1.7M (-22.0%) | 0.84% -0.432 pp | 0.00% 0.000 pp | USD2.60 +19.2% | 28 qtrs — |
| 26 | GOLDMAN SACHS GROUP INC | 1.79M +1.5M (+498.2%) | 5.56M +4.8M (+605.1%) | 0.79% +0.654 pp | 0.00% +0.001 pp | USD2.89 +7.3% | 25 qtrs — |
| 27 | UBS GROUP AG | 1.77M -998.7K (-36.1%) | 5.49M -1.8M (-24.6%) | 0.78% -0.442 pp | 0.00% 0.000 pp | USD2.46 +26.0% | 27 qtrs — |
| 28 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.69M -43.9K (-2.5%) | 5.23M +677.0K (+14.9%) | 0.74% -0.022 pp | 0.00% +0.000 pp | USD4.05 -23.5% | 28 qtrs — |
| 29 | MB GENERATIONAL WEALTH, LLC | 1.61M +190.6K (+13.5%) | 4.98M +1.3M (+33.8%) | 0.70% +0.082 pp | 2.63% +0.271 pp | USD2.69 +15.2% | 2 qtrs — |
| 30 | BALYASNY ASSET MANAGEMENT L.P. | 1.52M +746.1K (+96.8%) | 4.70M +2.7M (+132.0%) | 0.67% +0.326 pp | 0.01% +0.003 pp | USD2.86 +8.4% | 4 qtrs — |
| 31 | NORTHERN TRUST CORP | 1.42M -78.9K (-5.3%) | 4.39M +458.4K (+11.7%) | 0.62% -0.037 pp | 0.00% +0.000 pp | USD2.72 +14.0% | 28 qtrs — |
| 32 | DEUTSCHE BANK AG\ | 1.28M +5.4K (+0.4%) | 3.98M +617.9K (+18.4%) | 0.56% +0.001 pp | 0.00% +0.000 pp | USD0.94 +229.8% | 28 qtrs — |
| 33 | AQR CAPITAL MANAGEMENT LLC | 1.12M +472.6K (+73.1%) | 3.47M +1.8M (+104.0%) | 0.49% +0.206 pp | 0.00% +0.001 pp | USD2.83 +9.5% | 2 qtrs — |
| 34 | WALLEYE CAPITAL LLC | 1.08M +531.4K (+97.4%) | 3.34M +1.9M (+132.6%) | 0.47% +0.232 pp | 0.01% +0.005 pp | USD2.86 +8.4% | 2 qtrs — |
| 35 | MONASHEE INVESTMENT MANAGEMENT LLC | 1.00M +1.0M (+100.0%) | 3.10M +3.1M (+100.0%) | 0.44% +0.439 pp | 1.75% +1.747 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 36 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 1.00M +1.0M (+100.0%) | 3.10M +3.1M (+100.0%) | 0.44% +0.439 pp | 0.15% +0.154 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 37 | HRT FINANCIAL LP | 956.9K +956.9K (+100.0%) | 2.97M +3.0M (+100.0%) | 0.42% +0.420 pp | 0.01% +0.009 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 38 | MORGAN STANLEY | 918.9K +352.5K (+62.2%) | 2.85M +1.4M (+91.2%) | 0.40% +0.154 pp | 0.00% +0.000 pp | USD1.92 +61.5% | 28 qtrs — |
| 39 | ALYESKA INVESTMENT GROUP, L.P. | 909.1K -1.0M (-52.4%) | 2.82M -2.2M (-43.9%) | 0.40% -0.441 pp | 0.01% -0.007 pp | USD0.95 +226.3% | 10 qtrs — |
| 40 | DIADEMA PARTNERS LP | 877.1K +52.3K (+6.3%) | 2.72M +549.8K (+25.3%) | 0.38% +0.022 pp | 0.47% -0.087 pp | USD1.16 +167.2% | 5 qtrs — |
| 41 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 750.3K +114.9K (+18.1%) | 2.33M +654.9K (+39.2%) | 0.33% +0.050 pp | 0.00% +0.000 pp | USD1.44 +115.3% | 4 qtrs — |
| 42 | CITADEL ADVISORS LLC | 704.8K -1.6M (-69.1%) | 2.18M -3.8M (-63.6%) | 0.31% -0.696 pp | 0.00% -0.001 pp | USD2.14 +44.9% | 28 qtrs — |
| 43 | RENAISSANCE TECHNOLOGIES LLC | 658.9K -2.3M (-77.9%) | 2.04M -5.8M (-73.9%) | 0.29% -1.022 pp | 0.00% -0.007 pp | USD1.19 +160.5% | 9 qtrs — |
| 44 | HENNION & WALSH ASSET MANAGEMENT, INC. | 653.0K +653.0K (+100.0%) | 2.02M +2.0M (+100.0%) | 0.29% +0.286 pp | 0.07% +0.070 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 45 | WELLINGTON MANAGEMENT GROUP LLP | 601.3K -40.4K (-6.3%) | 1.86M +176.4K (+10.5%) | 0.26% -0.019 pp | 0.00% +0.000 pp | USD2.63 +17.9% | 2 qtrs — |
| 46 | BARCLAYS PLC | 576.5K +555.5K (+2,637.1%) | 1.79M +1.8M (+8,501.7%) | 0.25% +0.244 pp | 0.00% +0.000 pp | USD3.03 +2.3% | 9 qtrs — |
| 47 | PLATINUM INVESTMENT MANAGEMENT LTD | 562.0K -202.2K (-26.5%) | 1.74M -267.7K (-13.3%) | 0.25% -0.090 pp | 0.40% +0.273 pp | USD1.00 +210.0% | 12 qtrs — |
| 48 | QUBE RESEARCH & TECHNOLOGIES LTD | 540.6K +331.8K (+158.9%) | 1.68M +1.1M (+205.2%) | 0.24% +0.145 pp | 0.00% +0.001 pp | USD2.29 +35.4% | 16 qtrs — |
| 49 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 528.1K +502.6K (+1,974.9%) | 1.64M +1.6M (+2,345.7%) | 0.23% +0.220 pp | 0.00% +0.004 pp | USD3.08 +0.6% | 2 qtrs — |
| 50 | IKARIAN CAPITAL, LLC | 500.0K +500.0K (+100.0%) | 1.55M +1.6M (+100.0%) | 0.22% +0.219 pp | 0.12% +0.121 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 51 | SILVERBACK ASSET MANAGEMENT LLC | 500.0K +— (+0.0%) | 1.55M +235.0K (+17.9%) | 0.22% -0.001 pp | 0.23% +0.101 pp | USD1.56 +98.7% | 4 qtrs — |
| 52 | INVESCO LTD. | 478.9K +126.8K (+36.0%) | 1.48M +558.6K (+60.3%) | 0.21% +0.055 pp | 0.00% +0.000 pp | USD2.04 +52.0% | 4 qtrs — |
| 53 | XTX TOPCO LTD | 456.3K +181.5K (+66.1%) | 1.41M +691.9K (+95.7%) | 0.20% +0.079 pp | 0.04% 0.000 pp | USD2.51 +23.5% | 5 qtrs — |
| 54 | EXOME ASSET MANAGEMENT LLC | 451.7K +— (+0.0%) | 1.40M +212.3K (+17.9%) | 0.20% -0.001 pp | 0.67% -0.050 pp | USD0.92 +237.0% | 7 qtrs — |
| 55 | BANK OF NEW YORK MELLON CORP | 447.9K -310.0 (-0.1%) | 1.39M +209.7K (+17.8%) | 0.20% -0.001 pp | 0.00% +0.000 pp | USD1.65 +87.9% | 28 qtrs — |
| 56 | JPMORGAN CHASE & CO | 428.9K +234.5K (+120.7%) | 1.33M +818.4K (+160.1%) | 0.19% +0.103 pp | 0.00% +0.000 pp | USD2.59 +19.7% | 28 qtrs — |
| 57 | WELLS FARGO & COMPANY/MN | 361.9K +245.3K (+210.2%) | 1.12M +815.1K (+265.7%) | 0.16% +0.107 pp | 0.00% +0.000 pp | USD2.57 +20.6% | 28 qtrs — |
| 58 | LPL FINANCIAL LLC | 358.9K +220.6K (+159.5%) | 1.11M +748.8K (+205.8%) | 0.16% +0.097 pp | 0.00% +0.000 pp | USD2.66 +16.5% | 3 qtrs — |
| 59 | ALGERT GLOBAL LLC | 332.3K +332.3K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.15% +0.146 pp | 0.02% +0.016 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 60 | RAFFERTY ASSET MANAGEMENT, LLC | 312.8K +312.8K (+100.0%) | 969.7K +969.7K (+100.0%) | 0.14% +0.137 pp | 0.00% +0.003 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 61 | MONACO ASSET MANAGEMENT SAM | 309.2K -1.1M (-77.6%) | 958.6K -2.7M (-73.6%) | 0.14% -0.471 pp | 0.17% -0.054 pp | USD0.96 +222.9% | 9 qtrs — |
| 62 | NUVEEN, LLC | 308.5K -768.6K (-71.4%) | 956.4K -1.9M (-66.2%) | 0.14% -0.339 pp | 0.00% -0.001 pp | USD2.31 +34.2% | 3 qtrs — |
| 63 | MACKENZIE FINANCIAL CORP | 306.5K -2.6K (-0.8%) | 954.3K +141.5K (+17.4%) | 0.13% -0.002 pp | 0.00% +0.000 pp | USD1.05 +195.2% | 6 qtrs — |
| 64 | TUDOR INVESTMENT CORP ET AL | 300.0K +300.0K (+100.0%) | 930.0K +930.0K (+100.0%) | 0.13% +0.132 pp | 0.00% +0.002 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 65 | SMITH, MOORE & CO. | 280.0K +— (+0.0%) | 868.0K +131.6K (+17.9%) | 0.12% 0.000 pp | 0.07% +0.009 pp | USD1.57 +97.5% | 18 qtrs — |
| 66 | EAM INVESTORS, LLC | 278.4K +— (+0.0%) | 863.1K +130.9K (+17.9%) | 0.12% 0.000 pp | 0.10% +0.012 pp | USD2.63 +17.9% | 2 qtrs — |
| 67 | JAIN GLOBAL LLC | 278.2K -776.2K (-73.6%) | 862.4K -1.9M (-68.9%) | 0.12% -0.342 pp | 0.00% -0.009 pp | USD2.63 +17.9% | 4 qtrs — |
| 68 | SEI INVESTMENTS CO | 228.9K +167.7K (+274.1%) | 709.6K +548.7K (+341.0%) | 0.10% +0.074 pp | 0.00% +0.001 pp | USD2.97 +4.4% | 2 qtrs — |
| 69 | SQUAREPOINT OPS LLC | 221.6K +221.6K (+100.0%) | 686.9K +686.9K (+100.0%) | 0.10% +0.097 pp | 0.00% +0.001 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 70 | RHUMBLINE ADVISERS | 214.9K -10.2K (-4.5%) | 666.1K +74.2K (+12.5%) | 0.09% -0.005 pp | 0.00% +0.000 pp | USD1.23 +152.0% | 3 qtrs — |
| 71 | ADAR1 CAPITAL MANAGEMENT, LLC | 212.5K +— (+0.0%) | 658.8K +99.9K (+17.9%) | 0.09% 0.000 pp | 0.05% -0.004 pp | USD0.92 +237.0% | 9 qtrs — |
| 72 | ATOM INVESTORS LP | 205.6K +73.1K (+55.1%) | 637.5K +288.9K (+82.9%) | 0.09% +0.032 pp | 0.05% +0.024 pp | USD1.81 +71.3% | 4 qtrs — |
| 73 | STONEPINE CAPITAL MANAGEMENT, LLC | 204.8K +— (+0.0%) | 634.8K +96.2K (+17.9%) | 0.09% 0.000 pp | 0.46% +0.026 pp | USD2.63 +17.9% | 2 qtrs — |
| 74 | D. E. SHAW & CO., INC. | 198.7K -50.1K (-20.1%) | 616.0K -38.4K (-5.9%) | 0.09% -0.022 pp | 0.00% +0.000 pp | USD2.31 +34.2% | 3 qtrs — |
| 75 | ALLIANCEBERNSTEIN L.P. | 190.2K +91.5K (+92.8%) | 589.7K +330.2K (+127.2%) | 0.08% +0.040 pp | 0.00% +0.000 pp | USD2.66 +16.5% | 3 qtrs — |
| 76 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 176.0K -159.9K (-47.6%) | 545.6K -337.8K (-38.2%) | 0.08% -0.071 pp | 0.01% -0.007 pp | USD0.96 +222.9% | 12 qtrs — |
| 77 | RUSSELL INVESTMENTS GROUP, LTD. | 171.1K -514.0K (-75.0%) | 530.3K -1.3M (-70.6%) | 0.08% -0.226 pp | 0.00% -0.002 pp | USD2.63 +17.9% | 2 qtrs — |
| 78 | JANE STREET GROUP, LLC | 155.6K -546.5K (-77.8%) | 482.3K -1.4M (-73.9%) | 0.07% -0.241 pp | 0.00% 0.000 pp | USD2.63 +17.9% | 22 qtrs — |
| 79 | MERIT FINANCIAL GROUP, LLC | 155.2K +20.5K (+15.2%) | 481.1K +126.8K (+35.8%) | 0.07% +0.009 pp | 0.00% +0.001 pp | USD2.69 +15.2% | 2 qtrs — |
| 80 | PANAGORA ASSET MANAGEMENT INC | 147.3K +117.4K (+392.6%) | 456.6K +378.0K (+480.7%) | 0.06% +0.052 pp | 0.00% +0.001 pp | USD3.00 +3.3% | 2 qtrs — |
| 81 | BIRCHVIEW CAPITAL, LP | 138.2K +— (+0.0%) | 428.3K +64.9K (+17.9%) | 0.06% 0.000 pp | 0.25% -0.024 pp | USD5.46 -43.2% | 18 qtrs — |
| 82 | BOOTHBAY FUND MANAGEMENT, LLC | 137.5K +137.5K (+100.0%) | 426.3K +426.3K (+100.0%) | 0.06% +0.060 pp | 0.01% +0.006 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 83 | PRELUDE CAPITAL MANAGEMENT, LLC | 136.2K +— (+0.0%) | 422.2K +64.0K (+17.9%) | 0.06% 0.000 pp | 0.03% +0.003 pp | USD0.93 +233.3% | 6 qtrs — |
| 84 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 127.3K +113.2K (+803.3%) | 394.6K +357.6K (+964.7%) | 0.06% +0.050 pp | 0.00% +0.004 pp | USD3.05 +1.6% | 4 qtrs — |
| 85 | POINT72 ASSET MANAGEMENT, L.P. | 125.0K +100.0K (+400.0%) | 387.5K +321.8K (+489.4%) | 0.05% +0.044 pp | 0.00% +0.000 pp | USD3.01 +3.0% | 2 qtrs — |
| 86 | PROFUND ADVISORS LLC | 116.5K +116.5K (+100.0%) | 361.2K +361.2K (+100.0%) | 0.05% +0.051 pp | 0.01% +0.011 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 87 | PRICE T ROWE ASSOCIATES INC /MD/ | 113.1K +12.5K (+12.4%) | 351.0K +86.0K (+32.5%) | 0.05% +0.005 pp | 0.00% +0.000 pp | USD1.34 +131.3% | 14 qtrs — |
| 88 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 111.4K +92.5K (+489.2%) | 345.2K +295.5K (+594.4%) | 0.05% +0.041 pp | 0.01% +0.005 pp | USD3.02 +2.6% | 2 qtrs — |
| 89 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 107.5K +20.2K (+23.1%) | 333.5K +104.0K (+45.3%) | 0.05% +0.009 pp | 0.00% +0.000 pp | USD1.58 +96.2% | 3 qtrs — |
| 90 | VICTORY CAPITAL MANAGEMENT INC | 105.6K +328.0 (+0.3%) | 327.2K +50.5K (+18.2%) | 0.05% +0.000 pp | 0.00% +0.000 pp | USD0.91 +240.7% | 10 qtrs — |
| 91 | ENTRYPOINT CAPITAL, LLC | 105.1K +53.8K (+105.0%) | 325.8K +190.9K (+141.6%) | 0.05% +0.024 pp | 0.13% +0.075 pp | USD2.87 +8.0% | 2 qtrs — |
| 92 | HB WEALTH MANAGEMENT, LLC | 95.9K +1.2K (+1.2%) | 297.4K +48.2K (+19.3%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD2.64 +17.4% | 6 qtrs — |
| 93 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 92.5K +92.5K (+100.0%) | 286.8K +286.8K (+100.0%) | 0.04% +0.041 pp | 0.01% +0.009 pp | USD3.10 +0.0% | 1 qtrs NEW |
| 94 | BNP PARIBAS ARBITRAGE, SNC | 89.5K -6.9K (-7.2%) | 277.4K +23.9K (+9.4%) | 0.04% -0.003 pp | 0.00% +0.000 pp | USD2.43 +27.6% | 27 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 27 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.00% | 94.3K | 0.34% |
| 2 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.00% | 12.9K | 0.40% |
| 3 | iShares Biotechnology ETF IBB | 0.00% | 259.5K | 0.44% |
| 4 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.00% | 2.0K | 0.19% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.00% | 1.9K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.00% | 27.9K | 0.35% |
| 7 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 41.4K | 0.06% |
| 8 | Xtrackers S&P 500 Swap UCITS ETF XS5G.L | 0.00% | 182.0K | 0.20% |
| 9 | Xtrackers S&P 500 Swap UCITS ETF 5C EUR Hedged XS5E.DE | 0.00% | 181.9K | 0.20% |
| 10 | Xtrackers S&P 500 Swap UCITS ETF 1C XSPU.L | 0.00% | 182.1K | 0.15% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.60
Bullish
Ratio by volume
1.31
Neutral
Buys
64
Sells
40
Shares acquired
21.66M
Shares disposed
16.59M
Cash buys
—
Cash sales
—
Net activity
+5,070,905
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-19 | Smith Robert Paul JR | Officer | D-Return | D | Stock Option (Right to Buy) | 562,500 | 2.88 | 1.62M | 0 | D | ↗ |
| 2026-03-19 | Peterson Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 0.45 | 168.8K | 375,000 | D | ↗ |
| 2026-03-19 | Hasnain Faheem | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 47,000 | 12.10 | 568.7K | 0 | D | ↗ |
| 2026-03-19 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 693,750 | 0.45 | 312.2K | 693,750 | D | ↗ |
| 2026-03-19 | Christian Waage | Officer | D-Return | D | Stock Option (Right to Buy) | 70,000 | 1.36 | 95.2K | 0 | D | ↗ |
| 2026-03-19 | Aranda Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 572,000 | 0.45 | 257.4K | 572,000 | D | ↗ |
| 2026-01-02 | Smith Robert Paul JR | Officer | A-Award | A | Common Stock | 93,750 | 0.00 | — | 260,898 | D | ↗ |
| 2026-01-02 | Peterson Caryn | Officer | A-Award | A | Common Stock | 84,500 | 0.00 | — | 259,333 | D | ↗ |
| 2026-01-02 | Hasnain Faheem | Director / Officer | A-Award | A | Common Stock | 280,000 | 0.00 | — | 837,793 | D | ↗ |
| 2026-01-02 | Giraudo Bryan | Officer | A-Award | A | Common Stock | 115,750 | 0.00 | — | 389,737 | D | ↗ |
| 2026-01-02 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 506,250 | 2.88 | 1.46M | 506,250 | D | ↗ |
| 2026-01-02 | Aranda Richard | Officer | A-Award | A | Common Stock | 93,750 | 0.00 | — | 463,106 | D | ↗ |
| 2025-10-01 | Smith Robert Paul JR | Officer | A-Award | A | Common Stock | 162,500 | 0.00 | — | 162,500 | D | ↗ |
| 2025-10-01 | Peterson Caryn | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 174,833 | D | ↗ |
| 2025-10-01 | Hasnain Faheem | Director / Officer | A-Award | A | Common Stock | 437,500 | 0.00 | — | 557,793 | D | ↗ |
| 2025-10-01 | Giraudo Bryan | Officer | A-Award | A | Common Stock | 181,250 | 0.00 | — | 273,987 | D | ↗ |
| 2025-10-01 | Christian Waage | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 710,934 | D | ↗ |
| 2025-10-01 | Aranda Richard | Officer | A-Award | A | Common Stock | 162,500 | 0.00 | — | 369,356 | D | ↗ |
| 2025-08-19 | Milligan Sandra | Director | P-Purchase | A | Common Stock | 26,050 | 1.92 | 50.0K | 58,050 | D | ↗ |
| 2025-06-25 | Quisel John D | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 1.36 | 156.4K | 115,000 | D | ↗ |
| 2025-06-25 | Nathan Steven D | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 1.36 | 156.4K | 115,000 | D | ↗ |
| 2025-06-25 | Milligan Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 1.36 | 156.4K | 115,000 | D | ↗ |
| 2025-06-25 | Drynan Skye | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 1.36 | 156.4K | 115,000 | D | ↗ |
| 2025-06-25 | Daniel Thomas O | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 1.36 | 156.4K | 115,000 | D | ↗ |
| 2025-06-25 | Cox Russell J. | Director | A-Award | A | Stock Option (Right to Buy) | 115,000 | 1.36 | 156.4K | 115,000 | D | ↗ |
| 2025-03-04 | Smith Robert Paul JR | Officer | A-Award | A | Stock Option (Right to Buy) | 572,000 | 1.13 | 646.4K | 572,000 | D | ↗ |
| 2025-03-04 | Peterson Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 440,000 | 1.13 | 497.2K | 440,000 | D | ↗ |
| 2025-03-04 | Hasnain Faheem | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,540,000 | 1.13 | 1.74M | 1,540,000 | D | ↗ |
| 2025-03-04 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 638,000 | 1.13 | 720.9K | 638,000 | D | ↗ |
| 2025-03-04 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 440,000 | 1.13 | 497.2K | 440,000 | D | ↗ |
| 2025-03-04 | Aranda Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 572,000 | 1.13 | 646.4K | 572,000 | D | ↗ |
| 2024-06-24 | Aranda Richard | Officer | S-Sale | D | Common Stock | 1,908 | 0.66 | 1.3K | 196,891 | — | ↗ |
| 2024-06-21 | Hasnain Faheem | Director / Officer | P-Purchase | A | Common Stock | 372,000 | 0.67 | 250.3K | 5,408,073 | — | ↗ |
| 2024-06-18 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 100,000 | 0.59 | 59.1K | 480,010 | — | ↗ |
| 2024-06-17 | Smith Robert Paul JR | Officer | P-Purchase | A | Common Stock | 25,000 | 0.60 | 15.1K | 25,000 | — | ↗ |
| 2024-06-06 | Quisel John D | Director | A-Award | A | Non-qualified stock option (Right to Buy) | 115,000 | 0.60 | 69.0K | 115,000 | — | ↗ |
| 2024-06-06 | Milligan Sandra | Director | A-Award | A | Non-qualified stock option (Right to Buy) | 115,000 | 0.60 | 69.0K | 115,000 | — | ↗ |
| 2024-06-06 | Daniel Thomas O | Director | A-Award | A | Non-qualified stock option (Right to Buy) | 115,000 | 0.60 | 69.0K | 115,000 | — | ↗ |
| 2024-06-06 | Cox Russell J. | Director | A-Award | A | Non-qualified stock option (Right to Buy) | 115,000 | 0.60 | 69.0K | 115,000 | — | ↗ |
| 2024-03-27 | Hasnain Faheem | Director / Officer | S-Sale | D | Common Stock | 23,172 | 1.16 | 26.8K | 120,293 | — | ↗ |
| 2024-03-27 | Giraudo Bryan | Officer | S-Sale | D | Common Stock | 6,430 | 1.16 | 7.4K | 92,737 | — | ↗ |
| 2024-03-27 | Christian Waage | Officer | S-Sale | D | Common Stock | 6,430 | 1.16 | 7.4K | 585,934 | — | ↗ |
| 2024-03-18 | Peterson Caryn | Officer | S-Sale | D | Common Stock | 4,018 | 1.33 | 5.3K | 49,833 | — | ↗ |
| 2024-03-18 | Aranda Richard | Officer | S-Sale | D | Common Stock | 4,018 | 1.33 | 5.3K | 198,799 | — | ↗ |
| 2024-03-11 | Nathan Steven D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-03-11 | Drynan Skye | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-02 | Peterson Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 0.97 | 363.8K | 375,000 | — | ↗ |
| 2024-01-02 | Hasnain Faheem | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,312,500 | 0.97 | 1.27M | 1,312,500 | — | ↗ |
| 2024-01-02 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 543,750 | 0.97 | 527.4K | 543,750 | — | ↗ |
| 2024-01-02 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 375,000 | 0.97 | 363.8K | 375,000 | — | ↗ |
| 2024-01-02 | Aranda Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 487,500 | 0.97 | 472.9K | 487,500 | — | ↗ |
| 2023-12-04 | Smith Robert Paul JR | Officer | A-Award | A | Stock Option (Right to Buy) | 1,500,000 | 0.97 | 1.45M | 1,500,000 | — | ↗ |
| 2023-11-28 | Quisel John D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-11-20 | Peterson Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.84 | 104.8K | 125,000 | — | ↗ |
| 2023-11-20 | Hasnain Faheem | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 437,500 | 0.84 | 366.6K | 437,500 | — | ↗ |
| 2023-11-20 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 181,250 | 0.84 | 151.9K | 181,250 | — | ↗ |
| 2023-11-20 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.84 | 104.8K | 125,000 | — | ↗ |
| 2023-11-20 | Aranda Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 162,500 | 0.84 | 136.2K | 162,500 | — | ↗ |
| 2023-11-15 | Milligan Sandra | Director | P-Purchase | A | Common Stock | 32,000 | 0.79 | 25.2K | 32,000 | — | ↗ |
| 2023-11-13 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 200,000 | 0.56 | 112.9K | 380,010 | — | ↗ |
| 2023-07-24 | Hasnain Faheem | Director / Officer | A-Award | A | Common Stock | 540,176 | 1.82 | 983.1K | 5,036,073 | — | ↗ |
| 2023-07-24 | Giraudo Bryan | Officer | A-Award | A | Common Stock | 54,020 | 1.82 | 98.3K | 180,010 | — | ↗ |
| 2023-07-24 | Christian Waage | Officer | A-Award | A | Common Stock | 13,504 | 1.82 | 24.6K | 45,892 | — | ↗ |
| 2023-06-22 | Aranda Richard | Officer | S-Sale | D | Common Stock | 1,814 | 1.29 | 2.3K | 197,574 | — | ↗ |
| 2023-06-08 | Milligan Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 1.26 | 44.1K | 35,000 | — | ↗ |
| 2023-06-08 | GALA RENEE D | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 1.26 | 44.1K | 35,000 | — | ↗ |
| 2023-06-08 | Daniel Thomas O | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 1.26 | 44.1K | 35,000 | — | ↗ |
| 2023-06-08 | Cox Russell J. | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 1.26 | 44.1K | 35,000 | — | ↗ |
| 2023-06-08 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 35,000 | 1.26 | 44.1K | 35,000 | — | ↗ |
| 2023-05-05 | Peterson Caryn | Officer | D-Return | D | Stock Option (Right to Buy) | 48,500 | 22.10 | 1.07M | 0 | — | ↗ |
| 2023-05-05 | Hasnain Faheem | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 1.36 | 1.02M | 750,000 | — | ↗ |
| 2023-05-05 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 1.36 | 81.6K | 60,000 | — | ↗ |
| 2023-05-05 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 47,667 | 1.36 | 64.8K | 47,667 | — | ↗ |
| 2023-05-05 | Aranda Richard | Officer | D-Return | D | Stock Option (Right to Buy) | 190,000 | 11.94 | 2.27M | 0 | — | ↗ |
| 2023-04-04 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 55,000 | 1.02 | 56.1K | 125,990 | — | ↗ |
| 2023-03-20 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 211,500 | 1.21 | 255.9K | 211,500 | — | ↗ |
| 2023-03-20 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 157,500 | 1.21 | 190.6K | 157,500 | — | ↗ |
| 2023-03-16 | Peterson Caryn | Officer | S-Sale | D | Common Stock | 7,564 | 1.10 | 8.3K | 53,851 | — | ↗ |
| 2023-03-16 | Carter Laura | Officer | S-Sale | D | Common Stock | 6,029 | 1.10 | 6.6K | 76,263 | — | ↗ |
| 2023-03-16 | Aranda Richard | Officer | S-Sale | D | Common Stock | 7,563 | 1.10 | 8.3K | 199,388 | — | ↗ |
| 2022-12-07 | Peterson Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 157,500 | 0.00 | — | 157,500 | — | ↗ |
| 2022-12-07 | Hasnain Faheem | Officer | A-Award | A | Stock Option (Right to Buy) | 544,500 | 0.00 | — | 544,500 | — | ↗ |
| 2022-12-07 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 211,500 | 0.00 | — | 211,500 | — | ↗ |
| 2022-12-07 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 157,500 | 0.00 | — | 157,500 | — | ↗ |
| 2022-12-07 | Carter Laura | Officer | A-Award | A | Stock Option (Right to Buy) | 157,500 | 0.00 | — | 157,500 | — | ↗ |
| 2022-12-07 | Aranda Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 157,500 | 0.00 | — | 157,500 | — | ↗ |
| 2022-10-24 | Peterson Caryn | Officer | S-Sale | D | Common Stock | 4,757 | 12.07 | 57.4K | 61,415 | — | ↗ |
| 2022-10-24 | Carter Laura | Officer | S-Sale | D | Common Stock | 4,876 | 12.07 | 58.9K | 82,292 | — | ↗ |
| 2022-10-24 | Aranda Richard | Officer | S-Sale | D | Common Stock | 4,757 | 12.07 | 57.4K | 205,430 | — | ↗ |
| 2022-07-15 | Hasnain Faheem | Officer | P-Purchase | A | Common Stock | 138,696 | 7.21 | 1,000.0K | 3,617,325 | — | ↗ |
| 2022-07-15 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 13,869 | 7.21 | 100.0K | 20,990 | — | ↗ |
| 2022-07-15 | Christian Waage | Officer | P-Purchase | A | Common Stock | 6,934 | 7.21 | 50.0K | 13,888 | — | ↗ |
| 2022-07-15 | Carter Laura | Officer | P-Purchase | A | Common Stock | 6,934 | 7.21 | 50.0K | 87,168 | — | ↗ |
| 2022-07-01 | Carter Laura | Officer | S-Sale | D | Common Stock | 8,808 | 8.25 | 72.6K | 80,234 | — | ↗ |
| 2022-06-22 | Aranda Richard | Officer | S-Sale | D | Common Stock | 1,778 | 6.88 | 12.2K | 209,897 | — | ↗ |
| 2022-06-09 | Milligan Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-06-09 | GALA RENEE D | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-06-09 | Daniel Thomas O | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-06-09 | Cox Russell J. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-06-09 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-06-09 | Bilenker Joshua H. | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2022-05-04 | Carter Laura | Officer | S-Sale | D | Common Stock | 1,262 | 7.20 | 9.1K | 89,042 | — | ↗ |
| 2022-03-23 | Hasnain Faheem | Officer | S-Sale | D | Common Stock | 19,035 | 8.92 | 169.7K | 143,465 | — | ↗ |
| 2022-03-23 | Giraudo Bryan | Officer | S-Sale | D | Common Stock | 10,722 | 8.92 | 95.6K | 99,167 | — | ↗ |
| 2022-03-23 | Christian Waage | Officer | S-Sale | D | Common Stock | 10,722 | 8.92 | 95.6K | 579,008 | — | ↗ |
| 2022-03-16 | Peterson Caryn | Officer | S-Sale | D | Common Stock | 6,279 | 8.28 | 52.0K | 66,172 | — | ↗ |
| 2022-03-16 | Carter Laura | Officer | S-Sale | D | Common Stock | 5,002 | 8.28 | 41.4K | 90,304 | — | ↗ |
| 2022-03-16 | Aranda Richard | Officer | S-Sale | D | Common Stock | 6,278 | 8.28 | 52.0K | 211,675 | — | ↗ |
| 2022-01-06 | Peterson Caryn | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 11.94 | 2.27M | 190,000 | — | ↗ |
| 2022-01-06 | Hasnain Faheem | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 650,000 | 11.94 | 7.76M | 650,000 | — | ↗ |
| 2022-01-06 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 265,000 | 11.94 | 3.16M | 265,000 | — | ↗ |
| 2022-01-06 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 11.94 | 2.27M | 190,000 | — | ↗ |
| 2022-01-06 | Carter Laura | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 11.94 | 2.27M | 190,000 | — | ↗ |
| 2022-01-06 | Aranda Richard | Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 11.94 | 2.27M | 190,000 | — | ↗ |
| 2021-10-25 | Peterson Caryn | Officer | S-Sale | D | Common Stock | 2,377 | 12.25 | 29.1K | 72,451 | — | ↗ |
| 2021-10-25 | Carter Laura | Officer | S-Sale | D | Common Stock | 2,377 | 12.25 | 29.1K | 95,306 | — | ↗ |
| 2021-10-25 | Aranda Richard | Officer | S-Sale | D | Common Stock | 2,377 | 12.25 | 29.1K | 217,432 | — | ↗ |
| 2021-09-16 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 10.54 | 1.58M | 150,000 | — | ↗ |
| 2021-06-30 | Carter Laura | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 97,683 | — | ↗ |
| 2021-06-21 | Aranda Richard | Officer | — | D | Stock Option (Right to Buy) | 45,000 | 22.10 | 994.5K | 0 | — | ↗ |
| 2021-06-10 | Milligan Sandra | Director | A-Award | A | Stock Option (Right to Buy) | 47,000 | 8.93 | 419.7K | 47,000 | — | ↗ |
| 2021-06-09 | GALA RENEE D | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 8.97 | 210.8K | 23,500 | — | ↗ |
| 2021-06-09 | Daniel Thomas O | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 8.97 | 210.8K | 23,500 | — | ↗ |
| 2021-06-09 | Cox Russell J. | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 8.97 | 210.8K | 23,500 | — | ↗ |
| 2021-06-09 | Burow Kristina | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 8.97 | 210.8K | 23,500 | — | ↗ |
| 2021-06-09 | Bilenker Joshua H. | Director | A-Award | A | Stock Option (Right to Buy) | 23,500 | 8.97 | 210.8K | 23,500 | — | ↗ |
| 2021-05-03 | Carter Laura | Officer | — | D | Stock Option (Right to Buy) | 110,000 | 16.37 | 1.80M | 0 | — | ↗ |
| 2021-04-16 | Peterson Caryn | Officer | — | D | Stock Option (Right to Buy) | 86,444 | 2.61 | 225.6K | 0 | — | ↗ |
| 2021-03-23 | Salter-Cid Luisa | Officer | S-Sale | D | Common Stock | 5,491 | 9.48 | 52.1K | 206,065 | — | ↗ |
| 2021-03-23 | Giraudo Bryan | Officer | S-Sale | D | Common Stock | 5,490 | 9.48 | 52.0K | 109,889 | — | ↗ |
| 2021-03-23 | Christian Waage | Officer | S-Sale | D | Common Stock | 5,490 | 9.48 | 52.1K | 588,199 | — | ↗ |
| 2021-02-25 | Salter-Cid Luisa | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 9.79 | 881.1K | 90,000 | — | ↗ |
| 2021-02-25 | Hasnain Faheem | Director / Officer | A-Award | A | Common Stock | 162,500 | 0.00 | — | 162,500 | — | ↗ |
| 2021-02-25 | Giraudo Bryan | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 9.79 | 881.1K | 90,000 | — | ↗ |
| 2021-02-25 | Christian Waage | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 9.79 | 881.1K | 90,000 | — | ↗ |
| 2020-10-14 | Hasnain Faheem | Director | P-Purchase | A | Common Stock | 96,520 | 10.36 | 1,000.0K | 3,478,629 | — | ↗ |
| 2020-10-14 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 3,000 | 10.01 | 30.0K | 7,121 | — | ↗ |
| 2020-10-14 | Christian Waage | Officer | P-Purchase | A | Common Stock | 2,500 | 9.53 | 23.8K | 6,954 | — | ↗ |
| 2020-06-23 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 2,000 | 12.96 | 25.9K | 4,121 | — | ↗ |
| 2020-06-17 | Hasnain Faheem | Director | A-Award | A | Stock Option (right to buy) | 47,000 | 12.10 | 568.7K | 47,000 | — | ↗ |
| 2020-06-17 | GALA RENEE D | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 12.10 | 284.4K | 23,500 | — | ↗ |
| 2020-06-17 | Daniel Thomas O | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 12.10 | 284.4K | 23,500 | — | ↗ |
| 2020-06-17 | Cox Russell J. | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 12.10 | 284.4K | 23,500 | — | ↗ |
| 2020-06-17 | Burow Kristina | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 12.10 | 284.4K | 23,500 | — | ↗ |
| 2020-06-17 | Bilenker Joshua H. | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 12.10 | 284.4K | 23,500 | — | ↗ |
| 2020-02-14 | Salter-Cid Luisa | Officer | A-Award | A | Common Stock | 46,500 | 0.00 | — | 166,556 | — | ↗ |
| 2020-02-14 | Gujrathi Sheila | Director / Officer | A-Award | A | Stock Option (right to buy) | 292,000 | 14.55 | 4.25M | 292,000 | — | ↗ |
| 2020-02-14 | Giraudo Bryan | Officer | A-Award | A | Stock Option (right to buy) | 71,500 | 14.55 | 1.04M | 71,500 | — | ↗ |
| 2020-02-14 | Dupont Jakob | Officer | A-Award | A | Common Stock | 46,500 | 0.00 | — | 46,500 | — | ↗ |
| 2020-02-14 | Christian Waage | Officer | A-Award | A | Common Stock | 46,500 | 0.00 | — | 547,998 | — | ↗ |
| 2019-12-31 | Salter-Cid Luisa | Officer | G-Gift | D | Common Stock | 4,000 | 0.00 | — | 120,056 | — | ↗ |
| 2019-12-30 | Dupont Jakob | Officer | M-Exempt | D | Non-qualified stock option (Right to Buy) | 40,000 | 10.71 | 428.4K | 439,317 | — | ↗ |
| 2019-12-27 | Dupont Jakob | Officer | M-Exempt | D | Non-qualified stock option (Right to Buy) | 1,994 | 10.71 | 21.4K | 479,317 | — | ↗ |
| 2019-09-27 | Hasnain Faheem | Director | P-Purchase | A | Common Stock | 10,000 | 16.80 | 168.0K | 3,382,109 | — | ↗ |
| 2019-09-27 | Gujrathi Sheila | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 16.80 | 168.0K | 4,048,242 | — | ↗ |
| 2019-09-27 | Christian Waage | Officer | P-Purchase | A | Common Stock | 1,000 | 16.65 | 16.7K | 4,454 | — | ↗ |
| 2019-09-26 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 1,121 | 16.78 | 18.8K | 2,121 | — | ↗ |
| 2019-09-20 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 183,607 | 21.96 | 4.03M | 6,553,416 | — | ↗ |
| 2019-09-18 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 45,600 | 21.88 | 997.6K | 6,737,023 | — | ↗ |
| 2019-09-17 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 23,400 | 21.62 | 505.8K | 6,782,623 | — | ↗ |
| 2019-09-16 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 13,213 | 21.52 | 284.3K | 6,806,023 | — | ↗ |
| 2019-09-11 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 80,403 | 21.31 | 1.71M | 6,819,236 | — | ↗ |
| 2019-09-10 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 32,373 | 21.00 | 679.9K | 6,899,639 | — | ↗ |
| 2019-09-06 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 8,700 | 21.51 | 187.1K | 6,932,012 | — | ↗ |
| 2019-09-05 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 12,704 | 21.60 | 274.4K | 6,940,712 | — | ↗ |
| 2019-08-29 | Salter-Cid Luisa | Officer | S-Sale | D | Common Stock | 26,252 | 20.09 | 527.3K | 124,056 | — | ↗ |
| 2019-08-28 | Salter-Cid Luisa | Officer | S-Sale | D | Common Stock | 23,748 | 19.65 | 466.7K | 150,308 | — | ↗ |
| 2019-06-10 | Stampacchia Otello | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 23,500 | 19.54 | 459.2K | 23,500 | — | ↗ |
| 2019-06-10 | GALA RENEE D | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 19.54 | 459.2K | 23,500 | — | ↗ |
| 2019-06-10 | Daniel Thomas O | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 19.54 | 459.2K | 23,500 | — | ↗ |
| 2019-06-10 | Cox Russell J. | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 19.54 | 459.2K | 23,500 | — | ↗ |
| 2019-06-10 | Burow Kristina | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 19.54 | 459.2K | 23,500 | — | ↗ |
| 2019-06-10 | Bilenker Joshua H. | Director | A-Award | A | Stock Option (right to buy) | 23,500 | 19.54 | 459.2K | 23,500 | — | ↗ |
| 2019-05-30 | Giraudo Bryan | Officer | P-Purchase | A | Common Stock | 1,000 | 18.70 | 18.7K | 1,000 | — | ↗ |
| 2019-03-25 | Salter-Cid Luisa | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 22.10 | 2.65M | 120,000 | — | ↗ |
| 2019-03-25 | Hasnain Faheem | Director / Officer | A-Award | A | Stock Option (right to buy) | 43,500 | 22.10 | 961.4K | 43,500 | — | ↗ |
| 2019-03-25 | Gujrathi Sheila | Director / Officer | A-Award | A | Stock Option (right to buy) | 380,000 | 22.10 | 8.40M | 380,000 | — | ↗ |
| 2019-03-25 | Giraudo Bryan | Officer | A-Award | A | Stock Option (right to buy) | 145,000 | 22.10 | 3.20M | 145,000 | — | ↗ |
| 2019-03-25 | Dupont Jakob | Officer | A-Award | A | Stock Option (right to buy) | 65,000 | 22.10 | 1.44M | 65,000 | — | ↗ |
| 2019-03-25 | Christian Waage | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 22.10 | 2.32M | 105,000 | — | ↗ |
| 2019-02-12 | Omega Fund V, L.P. | 10% Owner | C-Conversion | D | Series Seed Preferred Stock | 20,000,000 | 0.00 | — | 0 | — | ↗ |
| 2019-02-12 | Hasnain Faheem | Director / Officer | C-Conversion | D | Series A Preferred Stock | 185,984 | 0.00 | — | 0 | — | ↗ |
| 2019-02-12 | Gujrathi Sheila | Director / Officer | C-Conversion | D | Series B Preferred Stock | 55,957 | 0.00 | — | 0 | — | ↗ |
| 2019-02-12 | Giraudo Bryan | Officer | C-Conversion | D | Series A Preferred Stock | 57,142 | 0.00 | — | 0 | — | ↗ |
| 2019-02-12 | Daniel Thomas O | Director | C-Conversion | A | Common Stock | 38,095 | 0.00 | — | 38,095 | — | ↗ |
| 2019-02-12 | Cox Russell J. | Director | P-Purchase | A | Common Stock | 7,200 | 16.00 | 115.2K | 7,200 | — | ↗ |
| 2019-02-12 | Christian Waage | Officer | C-Conversion | D | Series B Preferred Stock | 15,543 | 0.00 | — | 0 | — | ↗ |
| 2019-02-12 | Burow Kristina | Director | C-Conversion | D | Series B Preferred Stock | 1,554,388 | 0.00 | — | 0 | — | ↗ |
| 2019-02-12 | ARCH Venture Partners IX, LLC | 10% Owner | C-Conversion | A | Common Stock | 345,419 | 0.00 | — | 4,027,958 | — | ↗ |
| 2019-02-07 | Salter-Cid Luisa | Officer | — | D | Common Stock | 0 | 0.00 | — | 174,056 | — | ↗ |
| 2019-02-07 | Omega Fund V, L.P. | 10% Owner | — | I | Series B Preferred Stock | 925,724 | 0.00 | — | 0 | — | ↗ |
| 2019-02-07 | Hasnain Faheem | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 3,313,510 | — | ↗ |
| 2019-02-07 | Gujrathi Sheila | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 3,976,212 | — | ↗ |
| 2019-02-07 | Giraudo Bryan | Officer | — | D | Series A Preferred Stock | 12,698 | 0.00 | — | 0 | — | ↗ |
| 2019-02-07 | GALA RENEE D | Director | — | D | Stock Option (Right to Buy) | 46,666 | 10.71 | 499.8K | 0 | — | ↗ |
| 2019-02-07 | Dupont Jakob | Officer | — | D | Stock Option (Right to Buy) | 481,311 | 10.71 | 5.15M | 0 | — | ↗ |
| 2019-02-07 | Daniel Thomas O | Director | — | D | Stock Option (Right to Buy) | 131,111 | 2.61 | 342.2K | 0 | — | ↗ |
| 2019-02-07 | Cox Russell J. | Director | — | D | Stock Option (Right to Buy) | 46,666 | 10.71 | 499.8K | 0 | — | ↗ |
| 2019-02-07 | Christian Waage | Officer | — | D | Common Stock | 0 | 0.00 | — | 499,948 | — | ↗ |
| 2019-02-07 | Burow Kristina | Director | — | I | Series A Preferred Stock | 3,682,539 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.1K
Shares Outstanding
234.70M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Faheem Hasnain Chairman, President and Chief Executive Officer | 649.6K | — | — | 1.39M | 254.8K | 4.0K | 2.30M | 60.51% | ↗ |
| 2 | 2025 | Bryan Giraudo Chief Operating Officer and Financial Officer | 519.8K | — | — | 576.7K | 152.9K | 4.0K | 1.25M | 46.01% | ↗ |
| 3 | 2025 | Robert Smith Chief Commercial Officer | 463.5K | 75.0K | — | 517.0K | 121.2K | 4.0K | 1.18M | 43.79% | ↗ |
| 4 | 2024 | Faheem Hasnain Chairman, President and Chief Executive Officer | 628.2K | — | — | 1.04M | 329.8K | 4.0K | 2.01M | 52.03% | ↗ |
| 5 | 2024 | Bryan Giraudo Chief Operating Officer and Financial Officer | 502.6K | — | — | 432.3K | 233.0K | 4.0K | 1.17M | 36.89% | ↗ |
| 6 | 2024 | Richard Aranda, M.D. Chief Medical Officer | 481.1K | — | — | 387.6K | 192.4K | 4.0K | 1.07M | 36.39% | ↗ |
| 7 | 2023 | Faheem Hasnain Chairman, President and Chief Executive Officer | 606.9K | — | — | 1.19M | 303.4K | — | 2.10M | 56.57% | ↗ |
| 8 | 2023 | Robert Smith Chief Commercial Officer | 35.8K | 100.0K | — | 1.20M | — | — | 1.33M | 89.80% | ↗ |
| 9 | 2023 | Bryan Giraudo Chief Operating Officer and Financial Officer | 485.6K | — | — | 579.8K | 218.5K | 4.0K | 1.29M | 45.02% | ↗ |
| 10 | 2023 | Richard Aranda, M.D. Chief Medical Officer | 461.9K | — | — | 381.0K | 185.9K | 4.0K | 1.03M | 36.89% | ↗ |
| 11 | 2022 | Faheem Hasnain Chairman, President and Chief Executive Officer | 591.6K | — | — | 6.36M | 310.9K | — | 7.26M | 87.57% | ↗ |
| 12 | 2022 | Bryan Giraudo Chief Operating Officer and Financial Officer | 473.4K | — | — | 2.58M | 213.2K | 4.0K | 3.27M | 78.87% | ↗ |
| 13 | 2022 | Richard Aranda, M.D. Chief Medical Officer | 443.3K | — | — | 1.86M | 177.9K | 4.0K | 2.48M | 74.81% | ↗ |
| 14 | 2021 | Faheem Hasnain Chairman, President and Chief Executive Officer | 574.4K | — | 1.59M | 2.27M | 321.2K | — | 4.75M | 81.15% | ↗ |
| 15 | 2021 | Bryan Giraudo Chief Operating Officer and Financial Officer | 438.5K | — | 440.6K | 1.73M | 210.3K | 3.0K | 2.83M | 76.93% | ↗ |
| 16 | 2021 | Christian Waage Executive Vice President, Technical Operations and Administration | 411.7K | — | 440.6K | 627.3K | 168.1K | 3.3K | 1.65M | 64.68% | ↗ |
| 17 | 2020 | Sheila Gujrathi, M.D. Former President and Chief Executive Officer | 494.0K | — | 2.76M | 3.04M | 276.7K | 642.0K | 7.21M | 80.42% | ↗ |
| 18 | 2020 | Bryan Giraudo Chief Operating Officer and Financial Officer | 416.7K | — | 676.6K | 745.3K | 176.4K | — | 2.01M | 70.57% | ↗ |
| 19 | 2020 | Bryan Giraudo Chief Financial Officer | 416.7K | — | 676.6K | 745.3K | 176.4K | — | 2.01M | 70.57% | ↗ |
| 20 | 2020 | Luisa Salter-Cid, Ph.D. Chief Scientific Officer | 402.2K | — | 676.6K | 745.3K | 170.8K | — | 1.99M | 71.28% | ↗ |
| 21 | 2020 | Christian Waage Executive Vice President and General Counsel | 399.8K | — | 676.6K | 745.3K | 168.7K | — | 1.99M | 71.44% | ↗ |
| 22 | 2020 | Christian Waage Executive Vice President, Technical Operations and Administration | 399.8K | — | 676.6K | 745.3K | 168.7K | — | 1.99M | 71.44% | ↗ |
| 23 | 2020 | Jakob Dupont, Ph.D. Former Chief Medical Officer | 162.6K | — | 676.6K | 745.3K | — | 57.7K | 1.64M | 86.58% | ↗ |
| 24 | 2020 | Faheem Hasnain Chairman, President and Chief Executive Officer | 71.5K | — | — | 396.6K | 54.3K | 76.4K | 598.8K | 66.23% | ↗ |
| 25 | 2019 | Sheila Gujrathi, M.D. Former President and Chief Executive Officer | 515.4K | 314.6K | — | 5.42M | — | — | 6.25M | 86.71% | ↗ |
| 26 | 2019 | Sheila Gujrathi, M.D. President and Chief Executive Officer and Former Chief Operating Officer | 515.4K | 314.6K | — | 5.42M | — | — | 6.25M | 86.71% | ↗ |
| 27 | 2019 | Bryan Giraudo Chief Operating Officer and Financial Officer | 400.0K | 180.8K | — | 2.07M | — | — | 2.65M | 78.06% | ↗ |
| 28 | 2019 | Bryan Giraudo Chief Financial Officer | 400.0K | 180.8K | — | 2.07M | — | — | 2.65M | 78.06% | ↗ |
| 29 | 2019 | Luisa Salter-Cid, Ph.D. Chief Scientific Officer | 376.9K | 171.8K | — | 1.71M | — | — | 2.26M | 75.71% | ↗ |
| 30 | 2019 | Christian Waage Executive Vice President, Technical Operations and Administration | 388.0K | 176.3K | — | 1.50M | — | — | 2.06M | 72.62% | ↗ |
| 31 | 2019 | Christian Waage Executive Vice President and General Counsel | 388.0K | 176.3K | — | 1.50M | — | — | 2.06M | 72.62% | ↗ |
| 32 | 2019 | Jakob Dupont, Ph.D. Former Chief Medical Officer | 440.0K | 183.0K | — | 926.4K | — | 88.0K | 1.64M | 56.57% | ↗ |
| 33 | 2019 | Faheem Hasnain Chairman, President and Chief Executive Officer | 199.9K | 99.8K | — | 619.9K | — | 62.6K | 982.2K | 63.12% | ↗ |
| 34 | 2018 | Sheila Gujrathi, M.D. President and Chief Executive Officer and Former Chief Operating Officer | 469.6K | 297.7K | 17.94M | — | — | — | 18.71M | 95.90% | ↗ |
| 35 | 2018 | Faheem Hasnain Chairman, President and Chief Executive Officer | 469.6K | 297.7K | 17.94M | — | — | — | 18.71M | 95.90% | ↗ |
| 36 | 2018 | Sheila Gujrathi, M.D. Former President and Chief Executive Officer | 469.6K | 297.7K | 17.94M | — | — | — | 18.71M | 95.90% | ↗ |
| 37 | 2018 | Faheem Hasnain Executive Chairman and Former Chief Executive Officer | 469.6K | 297.7K | 17.94M | — | — | — | 18.71M | 95.90% | ↗ |
| 38 | 2018 | Jakob Dupont, M.D. Chief Medical Officer | 20.2K | 85.0K | — | 3.42M | — | 3.2K | 3.53M | 96.93% | ↗ |
| 39 | 2018 | Jakob Dupont, Ph.D. Former Chief Medical Officer | 20.2K | 85.0K | — | 3.42M | — | 3.2K | 3.53M | 96.93% | ↗ |
| 40 | 2018 | Bryan Giraudo Chief Financial Officer | 260.6K | 132.2K | — | 1.80M | — | — | 2.19M | 82.08% | ↗ |
| 41 | 2018 | Luisa Salter-Cid, Ph.D. Chief Scientific Officer | 141.9K | 120.5K | — | 1.55M | — | 50.0K | 1.86M | 83.19% | ↗ |
| 42 | 2018 | Christian Waage EVP and General Counsel | 365.8K | 185.5K | — | 316.0K | — | — | 867.3K | 36.43% | ↗ |
| 43 | 2018 | Christian Waage Executive Vice President and General Counsel | 365.8K | 185.5K | — | 316.0K | — | — | 867.3K | 36.43% | ↗ |
| 44 | 2017 | Christian Waage EVP and General Counsel | — | — | 47.0K | — | — | — | 47.0K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman | 908.4K | male |
| Richard Aranda | Chief Medical Officer | 677.5K | — |
| Bryan Giraudo | Chief Operating Officer & Chief Financial Officer | 676.7K | male |
| Robert Smith | Chief Commercial Officer | 663.7K | male |
| Christian Waage | Executive Vice President of Technical Operations & Administration | 583.2K | male |
| Conor O'Donovan | Senior Vice President of Regulatory Affairs | — | male |
| Jeanine Anthony | Senior Vice President of Marketing | — | female |
| Jeff Boerneke | General Counsel & Secretary | — | male |
| Kelly Dawson | Senior Vice President of Program Team Lead | — | — |
| Louis K. Cherico | Senior Vice President of Finance & Treasury | — | male |
| Matt Cravets | Senior Vice President of Biometrics | — | male |
| Robert F. Roscigno | Senior Vice President of Clinical Development of Pulmonary Vascular Disease | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GOSS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
